Thank you very much.
Among my key points, first was to describe our industry, the importance of pharmaceutical manufacturing and exporting in Canada and many other jurisdictions as well. There was the importance of ensuring that the TPP does not erect new barriers to trade in generic pharmaceuticals for Canadian companies and also for all TPP member countries. Then also I was providing some of the information that Jim unfortunately had to skip over in his presentation, some of the kinds of things that we would like to see in trade agreements beyond regulatory cooperation and harmonization, things pertaining to intellectual property like an early working exception.
So Canada, for example, has a very strong early working exception for generic medicines, which ensures that generic medicines can access the market as soon as the patent expires, so that it doesn't create an extra delay there. I talked about best mode patent disclosure, so again, being able to have disclosed within a patent the most efficient way of creating an invention.
Also, I noted the incentives to help generics challenge weak or frivolous patents, because again countries rely on the generic pharmaceutical industry to challenge weak and frivolous patents to bring competition to the market, so providing incentives to ensure companies can do that is also viewed as very important to our industry.